Who is sponsoring NCT03783832?

NCT03783832 is sponsored by Aquitania Opthalmologica.

What drugs are being tested in NCT03783832?

Interventions in NCT03783832: OCT ANGIOGRAPHY DATA.

What condition does NCT03783832 study?

NCT03783832 studies Diabetic Macular Edema.

Is NCT03783832 still recruiting?

NCT03783832 is currently status unknown. Last updated 21 December 2018.

Last reviewed 2018-12-21 · How we verify

NCT03783832: DOCTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography

Status unknown Last updated 21 December 2018

What this trial tests

trial testing OCT ANGIOGRAPHY DATA in Diabetic Macular Edema in 48 participants. Status unknown.

Timeline

19 June 2018

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Aquitania Opthalmologica
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	48
Start date	19 June 2018
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	6 locations across France

Drugs / interventions tested

OCT ANGIOGRAPHY DATA

Conditions studied

Diabetic Macular Edema — all drugs for Diabetic Macular Edema →

Sponsor

Aquitania Opthalmologica

Who can join

18 and older, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-interventional, longitudinal, retrospective and prospective, non-controlled, single arm study in naive or non-naive patients with diabetic macular edema for which aflibercept (EYLEA®) therapy is indicated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03783832 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aquitania Opthalmologica
Last refreshed: 21 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03783832.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing